Back to Index
Gregory Idos, MD
Assistant Professor of Clinical Medicine
IRD 708 Off Campus Los Angeles
+1 323 442 1283


Having trained in Boston at Brigham and Women’s Hospital and Dana Farber Cancer Center under the direction of national experts, Dr. Idos has an extensive background in caring for patients with hereditary colorectal cancer syndromes, notably Lynch Syndrome and familial adenomatous polyposis (FAP). Currently, he works with Stephen Gruber MD, PhD, MPH, Director of USC Norris Comprehensive Cancer Center, as part of the Norris Cancer Genetics Clinic. The Cancer Genetics Clinic specializes in care for persons with a personal or family history of cancer who may benefit from genetic testing and counseling to understand and manage their risk of cancer.

In addition, Dr. Idos’ research interest is focused on the study of gastrointestinal cancer and cancer chemoprevention. Currently, he directs studies aimed at understanding the use of genetic information for the overall risk reduction and prevention of cancer.


Brigham and Women's Hospital, Harvard Medical School: Fellowship Teaching Award, 2009-2010

LAC+USC Medical Center: Senior Resident of the Year, 2008-2009

LAC+USC Medical Center: Intern of the Year, 2006-2007

Howard Hughes Medical Institute: Undergraduate Research Fellow, 1998-1999


Mental Illness Is Not Associated with Adherence to Colorectal Cancer Screening: Results from the California Health Interview Survey. Dig Dis Sci. 2016 Nov 7. View in: PubMed

Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohort. Cancer Genet. 2016 Apr; 209(4):130-7. View in: PubMed

A novel BAP1 mutation is associated with melanocytic neoplasms and thyroid cancer. Cancer Genet. 2016 Mar; 209(3):75-81. View in: PubMed

Corrigendum: Genome-wide association study of colorectal cancer identifies six new susceptibility loci. Nat Commun. 2015; 6:8739. View in: PubMed

Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Pancreas. 2012 Nov; 41(8):1195-205. View in: PubMed

Protein partners of C/EBPepsilon. Exp Hematol. 2004 Dec; 32(12):1173-81. View in: PubMed

RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia. Oncogene. 2004 Oct 14; 23(47):7846-53. View in: PubMed

Identification of interaction partners and substrates of the cyclin A1-CDK2 complex. J Biol Chem. 2004 Aug 6; 279(32):33727-41. View in: PubMed

Successive increases in human cyclin A1 promoter activity during spermatogenesis in transgenic mice. Int J Mol Med. 2003 Mar; 11(3):311-5. View in: PubMed

Cyclin A1 directly interacts with B-myb and cyclin A1/cdk2 phosphorylate B-myb at functionally important serine and threonine residues: tissue-specific regulation of B-myb function. Blood. 2001 Apr 1; 97(7):2091-7. View in: PubMed

Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res. 2001 Jan 15; 61(2):647-53. View in: PubMed

Methylation of the cyclin A1 promoter correlates with gene silencing in somatic cell lines, while tissue-specific expression of cyclin A1 is methylation independent. Mol Cell Biol. 2000 May; 20(9):3316-29. View in: PubMed

c-myb transactivates the human cyclin A1 promoter and induces cyclin A1 gene expression. Blood. 1999 Dec 15; 94(12):4255-62. View in: PubMed

Cloning of the cyclin A1 genomic structure and characterization of the promoter region. GC boxes are essential for cell cycle-regulated transcription of the cyclin A1 gene. J Biol Chem. 1999 Apr 16; 274(16):11220-8. View in: PubMed

Powered bySC CTSI